Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 19/20 | 0.65 |
| ▸ | PAK4 | O96013 | 1/20 | 0.63 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.63 |
| ▸ | CX3CR1 | P49238 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL843318 | 0.87 | CXCR2 (0.50) | CXCR2PAK4CXCR1CX3CR1 | |
| SCHEMBL13980260 | 0.84 | CXCR2 (0.66) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL842213 | 0.83 | CXCR2 (0.48) | CXCR2PAK4CXCR1CX3CR1 | |
| SCHEMBL6859607 | 0.81 | CXCR2 (0.72) | CXCR2PAK4CXCR1CX3CR1 | |
| SCHEMBL215475 | 0.81 | PAK4 (0.60) | CXCR2PAK4CXCR1CX3CR1 | |
| SCHEMBL6865488 | 0.81 | CXCR2 (0.69) | CXCR2PAK4CXCR1CX3CR1 | |
| SCHEMBL5035710 | 0.80 | CXCR2 (0.74) | CXCR2PAK4CXCR1CX3CR1 | |
| SCHEMBL6865964 | 0.79 | CXCR2 (0.67) | CXCR2PAK4CXCR1CX3CR1 | |
| SCHEMBL4488684 | 0.79 | CXCR2 (1.00) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL841694 | 0.78 | CXCR2 (0.84) | CXCR2CXCR1CX3CR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143261-B2 | Thiazolo (4,5-D) pyrimidine compounds | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20090281123-A1 | NOVEL THIAZOLO (4,5-D) PYRIMIDINE COMPOUNDS NOVEL COMPOUNDS | ASTRAZENECA UK LIMITED | 2009-11-12 | — | — | US | disclosed |
| US-7585867-B2 | Substituted thiazolo[4,5-d]pyrimidin-2(3H)-one | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| US-7585867-B2 | Substituted thiazolo[4,5-d]pyrimidin-2(3H)-one | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| US-7585867-B2 | Substituted thiazolo[4,5-d]pyrimidin-2(3H)-one | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| EP-1543013-B1 | 5-[[(2,3-Difluorophenyl)methyl]thio]-7-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]thiazolo[4,5-d]pyrimidin-2(3H)-one monosodium salt as CXCR2 antagonist | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | EP | disclosed |
| EP-1542974-B1 | 5-[((2,3-difluorophenyl)methyl)thio]-7-{[(1S,2S)-2-hydroxy-1-(hydroxymethyl)propyl]amino}thiazolo[4,5-d]pyrimidin-2(3H)-one as CXCR2 antagonist | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | EP | disclosed |
| EP-1542974-B1 | 5-[((2,3-difluorophenyl)methyl)thio]-7-{[(1S,2S)-2-hydroxy-1-(hydroxymethyl)propyl]amino}thiazolo[4,5-d]pyrimidin-2(3H)-one as CXCR2 antagonist | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | EP | disclosed |
| US-20080306262-A1 | Novel Compound | ASTRAZENECA AB, A SWEDISH CORPORATION | 2008-12-11 | — | — | US | disclosed |
| US-20080306262-A1 | Novel Compound | ASTRAZENECA AB, A SWEDISH CORPORATION | 2008-12-11 | — | — | US | disclosed |
| US-20060100221-A1 | Novel compound | ASTRAZENECA AB (SE) | 2006-05-11 | — | — | US | disclosed |
| US-20050272750-A1 | Novel compound | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | US | disclosed |
| US-6949643-B2 | Thiazolopytimidines and their use as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2005-09-27 | — | — | US | disclosed |
| EP-1385854-B1 | THIAZOLOPYRIMIDINES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2005-02-09 | — | — | EP | disclosed |
| US-20040224961-A1 | Novel thiazolo (4,5-D) pyrimidine compounds | ASTRAZENECA UK LIMITED, A BRITISH CORPORATION | 2004-11-11 | — | — | US | disclosed |
| US-6790850-B1 | Thiazolo(4,5-d)pyrimidine compounds | ASTRAZENECA UK LIMITED (GB) | 2004-09-14 | — | — | US | disclosed |
| US-20040157853-A1 | Thiazolopytimidines and their use as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-08-12 | — | — | US | disclosed |
| US-20040106628-A1 | Novel use | ASTRAZENECA AB (SE) | 2004-06-03 | — | — | US | disclosed |
| EP-1222195-B1 | NOVEL THIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | ASTRAZENECA UK LTD (GB) | 2004-01-14 | — | — | EP | disclosed |
| EP-1348709-A2 | Thiazolo (4,5-D) pyrimidine compounds | AstraZeneca UK Limited (GB) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157853-A1 | Thiazolopytimidines and their use as modulators of chemokine receptor activity | CCR5, CCR2, CX3CR1 | CXCR2 5/4885PAK4 1061/4885CXCR1 4/4885 |
| US-20040224961-A1 | Novel thiazolo (4,5-D) pyrimidine compounds | TYMS, DPYD, TYMP | CXCR2 378/4885PAK4 624/4885CXCR1 318/4885 |
| US-20060100221-A1 | Novel compound | SLC10A1, AVPR2, NPC1 | CXCR2 156/4885PAK4 1890/4885CXCR1 274/4885 |
| US-20090281123-A1 | NOVEL THIAZOLO (4,5-D) PYRIMIDINE COMPOUNDS NOVEL COMPOUNDS | TYMS, DPYD, TPMT | CXCR2 195/4885PAK4 328/4885CXCR1 265/4885 |
| US-20050272750-A1 | Novel compound | SLC10A1, AVPR2, NPC1 | CXCR2 156/4885PAK4 1890/4885CXCR1 274/4885 |
| US-20040106628-A1 | Novel use | CX3CR1, CNR1, ARRB1 | CXCR2 24/4885PAK4 3711/4885CXCR1 4/4885 |
| US-20080306262-A1 | Novel Compound | SLC10A1, AVPR2, NPC1 | CXCR2 156/4885PAK4 1890/4885CXCR1 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.